Nearly 40 years after the discovery of KRAS as an oncogene, two small molecule drugs, sotorasib (AMG 510) and adagrasib (MRTX849), were approved by the FDA for KRAS G12C–mutated NSCLC in 2021 and 2022 [9], respectively. This evidence concerns the gene KRAS and non-small cell lung carcinoma.